Immune-related encephalitis induced by durvalumab
10.3760/cma.j.cn114015-20220211-00114
- VernacularTitle:度伐利尤单抗致免疫相关性脑炎
- Author:
Quan WANG
1
;
Guangjie ZHOU
1
;
Jinfeng LI
1
Author Information
1. 山东大学附属威海市立医院药剂科，威海 264200
- Publication Type:Journal Article
- Keywords:
Immune checkpoint inhibitors;
Durvalumab;
Encephalitis
- From:
Adverse Drug Reactions Journal
2022;24(11):604-606
- CountryChina
- Language:Chinese
-
Abstract:
A 79-year-old male patient with small cell lung cancer (extensive stage) received EC chemotherapy regimen (IV infusions of etoposide 0.1 g on day 1 to 3 and carboplatin 400 mg on day 1) combined with immunotherapy (IV infusion of duvalizumab 620 mg on day 1), and 21 days was a cycle. On the 16th day of the 3rd cycle (the 58th day after the first medication), the patient developed left limb tremor and epilepsy. Biochemical examination of cerebrospinal fluid showed total protein 642 mg/L, white blood cell count 10×10 6/L. Electroencephalogram showed a small amount of sharp waves in bilateral lower temporal lobe. Immune-related encephalitis due to durvalumab was considered. Durvalumab was discontinued, glucocorticoid was given to suppress immune responses, and levetiracetam was given for antiepileptic treatment. Thirty-five days later, no obvious tremor appeared in the left limb and no seizure recurred.
